Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Pharmacol Ther 2014;141:1509
The 12 mg dose in TRIUMPH-4 led to a 28.7% loss over 68 weeks, while tirzepatide in the SURMOUNT-1 trial produced approximately 22.5% loss over 72 weeks
Chemical Society Reviews
This introduces variability in pharmacodynamics, as GLP-1RA penetration into specific brain regions may differ based on sex, compound properties, and age ( This raises important questions for ongoing trials such as EVOKE, which may uncover sex-specific differences and justify subsequent investigations of GLP-1 analogues in female populations
US$ 23.62
US$ 26.03
US$ 25.52
US$ 25.99
US$ 22.35
US$ 23.66
US$ 20.15
US$ 27.40
US$ 28.84
US$ 20.72
US$ 27.85
US$ 23.10
US$ 21.67
